Antisense oligonucleotide (ASO) drugs have shown significant progress in clinical development, targeting a wide range of diseases, from rare genetic disorders to more common conditions. Since the approval of the first ASO drug, Fomivirsen, in 1998, the pipeline has expanded substantially. Here are some key ASO drugs currently in clinical stages: 

Antisense oligonucleotides (ASOs) and small interfering RNAs (siRNAs) are both tools for modulating gene expression, but they differ in structure, mechanism, delivery, and applications. ASOs are single-stranded molecules designed to bind target RNA and alter its function, while siRNAs are double-stranded molecules that trigger RNA interference (RNAi) to degrade target mRNA. Below is a detailed comparison.

Antisense oligonucleotide (ASO) drugs have advanced significantly, establishing themselves as a versatile and effective platform for treating genetic and other complex diseases. Key progress includes the following: 

MicroRNA (miRNA) therapeutics are being actively developed, with several candidates progressing to clinical and preclinical stages. Below are examples from each category: